Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI of Edaravone and Taurine in Compound Edaravone Injection
NCT04218513Phase 1Completed
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Start
- May 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edaravone and taurine in ischemic stroke (3 arms), sponsored by Nanjing Yoko Biomedical Co., Ltd. Primary endpoints: Maximum Plasma Concentration (Cmax) of Edaravone at 24 hours, Area Under the Curve to Last Quantifiable Time Point (AUC0-t) of Edaravone at 24 hours and 1 more. Started May 2019; status: completed.
02
Drugs
edaravonetaurine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04218513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218513.